molecules transparent

Legal Notice

MCI Deutschland GmbH 
MCI | Germany – Berlin
Markgrafenstrasse 56
10117 Berlin, Germany
T: +49 30 204590
F: +49 30 2045950
www.mci-group.com
amp-europe@wearemci.com
Managing Director
Andreas Laube
Court of Jurisdiction
HRB 100620B Berlin
VAT Identification Number
DE 114 406 202

1. Content

MCI Deutschland GmbH reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected. All offers are not-binding and without obligation. Parts of the pages or the complete publication including all offers and information might be extended, changed or partly or completely deleted by MCI Deutschland GmbH without separate announcement.

2. Referrals and links

MCI Deutschland GmbH is not responsible for any contents linked or referred to from its pages – unless he has full knowledge of illegal contents and would be able to prevent the visitors of his site from viewing those pages. If any damage occurs by the use of information presented there, only the author of the respective pages might be liable, not the one who has linked to these pages. Furthermore MCI Deutschland GmbH is not liable for any postings or messages published by users of discussion boards, guest books or mailing lists provided on his page.

3. Copyright

MCI Deutschland GmbH intended not to use any copyrighted material for the publication or, if not possible, to indicate the copyright of the respective object.
The copyright for any material created by MCI Deutschland GmbH is reserved. Any duplication or use of objects such as diagrams, sounds or texts in other electronic or printed publications is not permitted without MCI Deutschland GmbH agreement.

4. Privacy policy

If the opportunity for the input of personal or business data (e-mail addresses, name, addresses) is given, the input of these data takes place voluntarily. The use and payment of all offered services are permitted – if and so far technically possible and reasonable – without specification of any personal data or under specification of anonymised data or an alias. The use of published postal addresses, telephone or fax numbers and email addresses for marketing purposes is prohibited; offenders sending unwanted spam messages will be punished.

5. Legal validity of this disclaimer

This disclaimer is to be regarded as part of the internet publication which you were referred from. If sections or individual terms of this statement are not legal or correct, the content or validity of the other parts remain uninfluenced by this fact. MCI Deutschland GmbH operates this website in Germany. German law forms the basis of the conditions of use and of all legal procedures.
Country of jurisdiction is Germany.

 

Federico Monzon

Federico A. Monzon is a molecular pathologist with extensive experience translating novel genomic technologies into clinical molecular tests, including leading studies on prostate and renal cancer genomics and the validation of one of the first FDA-cleared gene expression clinical assays for the diagnosis of tumors of unknown origin while at the University of Pittsburgh and Houston Methodist Hospital. At Invitae and Baylor Genetics laboratories, he pioneered the use of panel testing for hereditary cancers as well as cancer exome sequencing.

Dr. Monzon is a consultant on medical and scientific strategy for companies in the diagnostic space. Currently, he is Chief Medical Officer (CMO) at Delphi Diagnostics, a laboratory focused on providing genomic tools for the management of breast cancer patients. Prior to that, he served as CMP for Castle Diagnostics and served as Medical Director of Oncology and Medical Director for Latin America at Invitae Corporation. Previously, Dr. Monzon served as Director of Pathology at the Cancer Genetics Laboratory at Baylor College of Medicine. He earned his M.D. from the Universidad Nacional Autónoma de México (UNAM) and is board-certified by the American Board of Pathology in anatomic, clinical and molecular genetic pathology. Dr Monzon was the 2017 President of the Association for Molecular Pathology (AMP) and continues to be engaged in AMP and other professional societies to shape the future of clinical genomic medicine.

Soon!